Skip to contentV
Vaccinex, Inc.
V
VCNXVaccinex, Inc. Q1 2024 · 10-Q
Revenue$104.00K$104.00K−81.1% vs Q1 2023 Net Income-$3.90M-$3.90MN/M vs Q1 2023 EPS Diluted-$2.94-$2.94N/M vs Q1 2023 Operating Income-$5,074,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaccinex, Inc. · CIK 1205922 · Engraved from SEC EDGAR
Free Cash Flowderived-$4,632,000N/M Margins · derivedOperating margin-4878.8%−3972.3 pt vs Q1 2023
Net margin-3747.1%−2844.9 pt vs Q1 2023
ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end